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Introduction
Inherited thrombocytopenias are a group of disorders associated 
with bleeding of varying severity, depending both on the reduction 
in platelet count and any additional platelet dysfunction (1). The 
normal human platelet count ranges widely (150 × 109 to 400 × 109 
platelets/l) and is maintained within a narrow range for each indi-
vidual. This homeostasis requires a balance among thrombopoiesis, 
platelet senescence, and consumption. Heritable forms of thrombo-
cytopenia are usually caused by mutations in genes involved in plate-
let production and megakaryocytic differentiation. Over 20 forms 
of inherited thrombocytopenia have been described in the OMIM 
database (http://www.ncbi.nlm.nih.gov/omim); however, in approx-
imately 50% of patients, the causative gene remains unknown (2, 3). 
Identification of such genes is fundamental to providing information 
on proteins involved in normal platelet physiology and is critical for 
developing our understanding of disease pathogenesis.
To date, the UK Genotyping and Phenotyping of Platelets 
(GAPP) study (4) has investigated over 500 patients with exces-
sive bleeding of unknown etiology, identifying a platelet defect in 
approximately 60% of participants. A key criterion for recruitment 
is that known genetic causes of platelet dysfunction have been ruled 
out on the basis of functional studies and targeted gene sequenc-
ing. Platelets from patients recruited to this study undergo exten-
sive phenotypic analysis, including lumiaggregometry on a variety 
of platelet agonists and detailed analysis of platelet number and 
morphology. This is followed by whole-exome sequencing (WES), 
which has greatly enhanced the probability and speed of identifica-
tion of novel causative gene mutations in such conditions (5–7). In 
this study, we demonstrate how combined phenotyping and geno-
typing has enabled us to identify 3 single nucleotide variations in a 
gene that we believe to be novel, schlafen 14 (SLFN14), predicting 
substitutions of 3 consecutive amino acids in SLFN14, in 3 unrelated 
families displaying a moderate form of congenital thrombocytope-
nia and a strong bleeding history. These individuals had a more 
severe bleeding history than predicted on platelet count alone, 
with platelets displaying reduced aggregation and ATP secretion 
in response to several platelet agonists, including ADP, collagen, 
and protease-activated receptor-1–activating (PAR-1–activating) 
peptide. This phenotyping and genotyping approach has identified 
SLFN14 as causative gene for a form of thrombocytopenia.
Results and Discussion
There are approximately 3,000 patients with platelet function 
disorders associated with excessive bleeding within the UK Hae-
Inherited thrombocytopenias are a group of disorders that are characterized by a low platelet count and are sometimes 
associated with excessive bleeding that ranges from mild to severe. We evaluated 36 unrelated patients and 17 family 
members displaying thrombocytopenia that were recruited to the UK Genotyping and Phenotyping of Platelets (GAPP) 
study. All patients had a history of excessive bleeding of unknown etiology. We performed platelet phenotyping and 
whole-exome sequencing (WES) on all patients and identified mutations in schlafen 14 (SLFN14) in 12 patients from 3 
unrelated families. Patients harboring SLFN14 mutations displayed an analogous phenotype that consisted of moderate 
thrombocytopenia, enlarged platelets, decreased ATP secretion, and a dominant inheritance pattern. Three heterozygous 
missense mutations were identified in affected family members and predicted to encode substitutions (K218E, K219N, 
and V220D) within an ATPase-AAA-4, GTP/ATP-binding region of SLFN14. Endogenous SLFN14 expression was reduced in 
platelets from all patients, and mutant SLFN14 expression was markedly decreased compared with that of WT SLFN14 when 
overexpressed in transfected cells. Electron microscopy revealed a reduced number of dense granules in affected patients 
platelets, correlating with a decreased ATP secretion observed in lumiaggregometry studies. These results identify SLFN14 
mutations as cause for an inherited thrombocytopenia with excessive bleeding, outlining a fundamental role for SLFN14 in 
platelet formation and function.
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with reduced ATP secretion (Figure 2, A and B). The similar plate-
let phenotype in the affected individuals of family A was consis-
tent with a dominant mode of inheritance.
Exome sequencing of DNA from IV:2, IV:4, and III:3 in family 
A revealed 22,867, 23,334, and 23,153 sequence variations, respec-
tively. Comparisons with dbSNP build 135, the 1000 Genomes 
project database, and our in-house database (composed of >600 
exomes) identified 124, 137, and 128 heterozygous variants we 
believe to be novel, respectively. Only 8 variants were shared by 
the 3 affected patients, of which 4 resulted in amino acid changes, 
including 3 nonsynonymous variants and 1 frameshift deletion. 
Sanger sequencing of these remaining 4 variants in all individ-
uals in family A left 2 remaining candidate variants in NEMF 
(p.H962Y) and SLFN14 (p.V220D) that segregated with disease 
(Supplemental Table 1; supplemental material available online 
with this article; doi:10.1172/JCI80347DS1). The exomes of 35 
index patients with thrombocytopenia and/or secretion defects 
who had been recruited to the UK GAPP study were scrutinized 
for novel variants in either the NEMF or SLFN14 genes. Two fur-
ther heterozygous missense variants were identified in SLFN14 in 
affected members of family B (p.K219N) and family C (p.K218E) 
(Table 1 and Figure 1, A and B). All 3 missense mutations were 
predicted to result in substitutions in consecutive amino acids 
within the ATPase-AAA-4 domain of the protein encoded by 
SLFN14 (Figure 1B). These 3 SLFN14 variants are not present in 
the Exome Aggregation Consortium data set of 61,486 unrelated 
individuals, sequenced as part of various disease-specific and 
mophilia Comprehensive Care Centres, of which approximately 
10% have a reduced platelet count. A candidate gene mutation 
has not been identified in approximately 50% of these patients. 
Over 500 patients from 25 UK Haemophilia Comprehensive Care 
Centres with excessive bleeding and suspected platelet function 
disorders have been recruited to the UK GAPP study. Of these 
patients, 13% have been classified as having a thrombocytopenia 
of unknown cause. A strong family history of low platelet count and 
significant bleeding phenotype enabled prioritization of patients 
for gene identification studies. WES was performed and analysis 
was undertaken in 53 patients (36 index cases) displaying reduced 
platelet counts ranging from 15 × 109/l to 140 × 109/l. Over 3 gen-
erations, family A had 9 affected members with a strong bleed-
ing history and moderate thrombocytopenia, with platelet counts 
ranging from 74 × 109/l to 140 × 109/l (Figure 1A and Table 1). The 
proband, IV:4, was aged 31 years with a platelet count of 100 × 109/l 
when entering the study. Her history included frequent and severe 
cutaneous bruising, prolonged bleeding from minor wounds, 
menorrhagia, postpartum hemorrhage, and spontaneous muscle 
hematoma. Several other members of family A also had significant 
bleeding histories and moderate thrombocytopenia (Table 1).
The gold-standard test for platelet function is Born aggregom-
etry, but increased information can be obtained by real-time mea-
surement of secretion of ATP (lumiaggregometry) (8). We tested 
affected members of family A (III:2, III:3, IV:2, IV:4, and IV:5) and 
observed reduced aggregation to ADP (10 and 30 μM), collagen 
(3 μg/ml and 10 μg/ml), and PAR-1–activating peptide (100 μM), 
Table 1. Heterozygous SLFN14 mutations and Platelet Phenotyping in affected patients of the 3 families with thrombocytopenia, 
excessive bleeding and platelet secretion defects
Family/patient ID SLFN14  
nucleotide 
alterationA
Effect on 
SLFN14 
protein
Platelet 
count 
(×109/l)B
Mean platelet 
volume (fl)  
ISTH BAT scoreC Lumiaggregometry/flow  
cytometry defects
ATP secretion  
(nmol/1 × 108 platelets)D
A; II:1 c.659 T>A p.Val220Asp NA NA NA NA NA
A; III:2 c.659 T>A p.Val220Asp 140 9.1 5 ADP (10, 30, 100 μM), collagen  
(1, 3 μg/ml), PAR-1 (100 μM)
0.81
A; III:3 c.659 T>A p.Val220Asp 74 10.4 10 ADP (10 μM), collagen (3 μg/ml),  
PAR-1 (30 μM)
0.42
A; IV:2 c.659 T>A p.Val220Asp 110 9.3 13 ADP (10, 30 μM), collagen (1, 3 μg/ml),  
PAR-1 (100 μM)
ND
A; IV:4 c.659 T>A p.Val220Asp 100 11.1 22 ADP (30 μM), collagen (3 μg/ml),  
PAR-1 (100 μM) 
0.28
A; IV:5 c.659 T>A p.Val220Asp 116 11.2 21 ADP (10 μM), collagen (3 μg/ml),  
PAR-1 (30 μM)
0.48
B; II:3 c.657 A>T p.Lys219Asn 68 11.9 20 Flow cytometry reduced responses  
to high conc. CRP and PAR-1
NA
B; I:2 c.657 A>T p.Lys219Asn 83 11.9 13 ADP (10, 30 μM), collagen  
(3, 10 μg/ml), PAR-1 (100 μM)
0.63
C; II:2 c.652 A>G p.Lys218Glu 89 13.0 NA ADP (10, 100 μM), collagen  
(1, 3 μg/ml), PAR-1 (100 μM)
0.12
Heterozygous nucleotide changes present in SLFN14 and their predicted effects on the resulting protein are shown. Index cases are shown in bold. 
AAlterations are numbered according to positions in the NM_001129820. BMean platelet counts are shown. Normal reference range is 150 × 109 platelets/l 
to 400 × 109 platelets/l. Thrombocytopenia is defined as platelet count <150 × 109 platelets/l. For mean platelet volume, the reference range is 7.83–10.5 fl. 
CInternational Society on Thrombosis and Haemostasis bleeding assessment tool (BAT) score. The 95th percentile (score of 4) was calculated from healthy 
volunteers (17). DATP secreted in response to 100 μM PAR-1 receptor–specific peptide SFLLRN. The 5th percentile in healthy volunteers is 0.82 nmol/1 × 108 
platelets. conc., concentration; CRP, collagen-related peptide; NA, not available; ND, not detectable.
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II:3 was too low for lumiaggregometry (8), and so platelet func-
tion was analyzed by flow cytometry for P-selectin expression, 
revealing reduced responses to collagen-related peptide and 
PAR-1 peptide (Table 1). In line with this, lumiaggregometry on 
patient I:2 revealed deaggregation to ADP, collagen, and PAR-1 
and reduced ATP secretion (Table 1). These results are similar to 
those seen in affected members of family A (Figure 2, A and B).
The index case in family C (II:2) was 3 years old at the time 
of enrollment. His platelet count in whole blood was 89 × 109/l, 
and he was noted to bruise easily from a young age. Lumiag-
population genetic studies (http://exac.broadinstitute.org/gene/
ENSG00000236320) and the latest version of dbSNP build 138.
Affected members of families B and C had remarkably 
similar platelet counts and platelet function defects. Family 
B included 3 patients, of which 2 were recruited to the study 
(I:2 and II:3). The proband in family B (II:3) was 35 years old 
when recruited to the study with a platelet count of 68 × 109/l 
and a history of spontaneous epistaxis starting in childhood. Her 
mother (I:2) had a platelet count in whole blood of 83 × 109/l, 
with a less severe bleeding history. The platelet count in patient 
Figure 1. Identification of SLFN14 mutations in 3 unrelated families with a dominant form of thrombocytopenia. (A) Pedigrees from 3 families with 
moderate thrombocytopenia. Affected individuals are shaded; question marks denote that platelet count is unknown; asterisks indicate those patients 
whose exomes were sequenced; and arrows indicate nucleotide change. Representative Sanger electropherograms confirming SLFN14 mutations in 
patients are shown below the relevant families. (B) Linear domain organization of SLFN14 protein, showing the amino acid position of the 3 different 
missense SLFN14 mutations (K218E, K219N, and V220D) located in the ATPase-AAA-4 domain and conservation of the protein in higher order species.
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cell-cycle regulation, proliferation, and differentiation (10–14). 
Recently, data have been published suggesting an important func-
tion for SLFN14 as an endoribonuclease, regulating rRNA and 
ribosome-associated mRNA cleavage and translational control in 
rabbit reticulocytes (15).
Rowley et al. (16) previously described SLFN14 mRNA 
expression in human and murine platelets. We identified expres-
sion of SLFN14 mRNA and protein in immature and mature 
megakaryocytes derived from CD34+ hematopoietic progenitor 
cells isolated from cord blood (Supplemental Figure 2). Expres-
sion of SLFN14 protein was confirmed by Western blotting of 
platelets from 11 healthy individuals, normalized to GAPDH 
loading controls (Supplemental Figure 3). Levels of SLFN14 in 
healthy volunteers ranged from 1.0 to 2.3 arbitrary units (mean 
1.5, 95% CI 1.2–1.8).
gregometry findings in this patient are similar to those of study 
participants from families A and B, with a selective loss of 
response to ADP, collagen, and PAR-1 and normal responses to 
arachidonic acid (Table 1, Figure 2, and Supplemental Figure 1).
In humans and mice, SLFN14 is located in a SLFN cluster with 
other schlafen paralogs (9). Members of the SLFN family are highly 
conserved among mammalian species. SLFN family proteins con-
tain a unique motif of unknown function, the “SLFN box,” and 
an AAA domain. The AAA+ domain consists of a P-loop NTPase 
implicated in ATP/GTP binding and hydrolysis (10). The SLFN 
family members are divided into 3 groups. SLFN5, SLFN8, SLFN9, 
SLFN10, and SLFN14 all belong to group 3, although SLFN14 is 
unique in containing a putative nuclear localization RKRRR motif 
in its C-terminus extension (10). The SLFN family of proteins have 
been suggested to be critical for a variety of processes, including 
Figure 2. Platelet phenotyping of patients from the 3 families with SLFN14 mutations. (A) Representative impaired aggregation traces in platelet- 
rich plasma from patients from the 3 families (family A, IV:4; family B, I:2; family C, II:2; and representative control), following lumiaggregometry 
performed on undiluted platelet-rich plasma to assess the percentage aggregation after stimulation with ADP (10 μM), collagen (3 μg/ml), and PAR-1 
peptide (100 μM). (B) Reduced ATP secretion from dense granules in representative patients from each of the 3 families using Chronolume after stim-
ulation with PAR-1 peptide (100 μM). Lumiaggregometry studies shown in A and B were repeated once and performed on single platelet samples from 
multiple affected individuals (family A, n = 5; family B, n = 1; and family C, n = 1). (C) Flow cytometric assessment of platelet function in platelet-rich 
plasma from patient III.2 from family A (n = 1 from one experiment). Agonist responses are determined using anti-CD62P. IgGk1, isotype control. Data 
for healthy volunteers are shown as mean ± SD (n = 9). Data for healthy volunteers (1:3 dilution) (with PBS) are shown to demonstrate the effect of 
moderate thrombocytopenia alone on this assay.
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mutant gene/protein influences stability of the wild-type protein. 
Importantly, the reduction in SLFN14 levels in platelets from carriers 
of the SLFN14 variants was confirmed in overexpression studies, in 
which, despite unaltered transfection efficiency, average field-of-
view intensity measurements, and Western blot analysis demon-
strated a significant reduction in expression of all SLFN14 variant 
constructs compared with the that of the wild-type construct, i.e., SLF-
N14(K218E)-myc, SLFN14(K219N)-myc, and SLFN14(V220D)-myc 
expression was reduced to 5%, 8%, and 52% of SLFN14(WT)-myc 
expression, respectively (Supplemental Figure 4). The much larger 
reduction in both SLFN14(K218E)-myc and SLFN14(K219N)-myc 
expression may be a result of increased instability in these mutations 
in comparison to the SLFN14(V220D)-myc mutant.
The effect of SLFN14 variants on protein expression in platelets 
from affected family members was investigated by Western blotting 
(Figure 3A). Platelet lysates from carriers of the 3 SLFN14 variants 
showed a 65%–80% reduction in SLFN14 protein expression when 
compared with that of control platelets (Figure 3, A and B). Patient 
III:2 from family A expressing the p.V220D mutation demonstrated 
a reduction in SLFN14 expression to approximately 24% of that of 
control (P ≤ 0.001); patients I:2 and II:3 from family B expressing the 
K219N mutation showed a reduction to 33% (P ≤ 0.005) and 34% 
(P ≤ 0.001) of that of control, respectively; and patient II:2 from fam-
ily C expressing the K218E mutation showed a decrease to 19% of 
that of control (P ≤ 0.001). This reduction in SLFN14 levels in all 3 
families is over 50% despite the heterozygosity, suggesting that the 
Figure 3. Functional characterization of SLFN14 in patient platelets. (A) Representative Western blot analysis of healthy volunteer and patient platelet 
lysates, demonstrating decreased SLFN14 protein levels in patient platelets when compared with healthy individuals. (B) Densitometry quantification of 
4 independent Western blots (A) performed using a single platelet sample obtained from each patient or healthy volunteer. **P ≤ 0.005, ***P ≤ 0.001, 
compared with control, Student’s t test. (C) Whole-mount electron microscopy images showing reduced dense granules (δ) in patient platelets in com-
parison to healthy volunteer platelets. Scale bar: 2 μm.(D) Quantification of data in C. *P ≤ 0.05, ***P ≤ 0.001, compared with control, Student’s t test. 
40 platelets were analyzed per patient/healthy volunteer from a single platelet sample. All values are mean ± SEM.
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secretion, and provide a basis for future mechanistic studies. This 
is the first description to our knowledge of a major role for SLFN14 
in human disease.
Methods
Further methods are detailed in the Supplemental Methods.
Statistics. In studies in which statistical analyses were performed, 
a 2-tailed Student’s t test was used to generate P values. P values less 
than or equal to 0.05 were considered significant.
Study approval. The GAPP study was approved by the National 
Research Ethics Service Committee West Midlands – Edgbaston (REC 
reference 06/MRE07/36), and participants gave written informed 
consent in accordance with the Declaration of Helsinki. This study is 
registered at ISRCTN (http://www.isrctn.org) as ISRCTN77951167. 
The GAPP study is included in the National Institute for Health 
Research Non-Malignant Haematology study portfolio (ID 9858).
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Expression of SLFN14(WT)-myc in HEK293T cells revealed a 
punctate structure localized throughout the cytoplasm, with low 
level nuclear punctate staining also observed. No significant dif-
ference in protein localization was observed between overexpres-
sion of all SLFN14 mutants and the wild-type construct (Supple-
mental Figure 5).
The morphology of platelets from patients carrying heterozy-
gous SLFN14 mutations was examined by transmission electron 
microscopy. Compared with platelets from healthy volunteers, no 
significant difference in α granule number or platelet ultrastruc-
ture was observed (Supplemental Figure 6). A small increase in 
platelet area was also observed corresponding with data shown in 
Table 1; however, a statistically significant increase was observed 
only in patient I:2 of family B (P ≤ 0.005). (Supplemental Figure 6).
Whole-mount electron microscopy was used to quantify dense 
granules numbers within affected patient and healthy volunteers 
platelets, and a significant reduction in dense granule number 
was observed in patient platelets from families A and B, patients 
IV:4 and II:3, respectively (Figure 3, C and D). This observation 
correlates with the reduced ATP secretion measured by lumiag-
gregometry (Figure 2). Spreading of platelets on fibrinogen was 
not significantly different in platelets between affected individu-
als and healthy controls (Supplemental Figure 7).
In summary, we report 3 unrelated families with a dominantly 
inherited moderate thrombocytopenia, with a disproportionate 
bleeding phenotype. A combination of extensive platelet phenotyp-
ing and WES identified 3 mutations in SLFN14, which underlies a 
moderate thrombocytopenia with platelet secretion defects. The 
affected patients have a distinct platelet phenotype with decreased 
responses to ADP, collagen, and PAR-1, pointing toward a defect in 
the Gi signalling pathway. Reduced dense granule secretion may 
also result in a loss of positive feedback during platelet activation. 
Platelets from affected patients displayed a relatively normal ultra-
structure but show a significant reduction in dense granule number, 
correlating with lumiaggregometry data showing decreased ATP 
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